Iovance Biotherapeutics (IOVA) Goodwill & Intangibles (2023 - 2026)

Iovance Biotherapeutics (IOVA) has reported Goodwill & Intangibles for 4 consecutive years, with $329.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Goodwill & Intangibles rose 2.24% year-over-year to $329.7 million; the TTM figure through Mar 2026 stood at $329.7 million (up 2.24% YoY), while the FY2025 annual figure was $335.2 million, up 18.68% from the prior year.
• Goodwill & Intangibles fell to $329.7 million in Q1 2026 per IOVA's latest filing, from $335.2 million in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $335.3 million in Q3 2025 and bottomed at $223.6 million in Q3 2023.
• Historically, Goodwill & Intangibles has averaged $292.5 million across 4 years, with a median of $296.3 million in 2025.
• Annual changes were most pronounced in 2024 — Goodwill & Intangibles soared 49.19% — and 2025, when it grew 0.51%.
• Iovance Biotherapeutics' Goodwill & Intangibles stood at $229.3 million in 2023, then rose by 23.18% to $282.4 million in 2024, then grew by 18.68% to $335.2 million in 2025, then slipped by 1.63% to $329.7 million in 2026.
• Business Quant data shows IOVA's Goodwill & Intangibles at $329.7 million in Q1 2026, $335.2 million in Q4 2025, and $335.3 million in Q3 2025.